are concise point-of-care prescribing, dosing and administering information to Prior to the initial foscarnet infusion, establish diuresis by administering Prehydrate with mL NS or D5W before first infusion to decrease risk for nephrotoxicity. See prescribing information for dose adjustments for CrCl < Group: antiviral. Solution for injection, 24 mg/ml ml, ml [non-EDL]. General information. Foscarnet is a non-nucleoside pyrophosphate analogue given.
|Published (Last):||27 April 2004|
|PDF File Size:||20.34 Mb|
|ePub File Size:||18.7 Mb|
|Price:||Free* [*Free Regsitration Required]|
Foscarnet is a non-nucleoside pyrophosphate analogue given by intravenous infusion. It is excreted mainly by the kidneys, the pharmacokinetics are complicated by the high incidence of renal function impairment during therapy, and deposition into and subsequent release of foscarnet inforjation bone.
Terminal half-lives of up to 87 hours have been reported.
Foscarnet crossed the foscranet brain barrier in variable amounts. Treatment of cytomegalovirus end organ disease and maintenance of CMV retinitis. Treatment of resistant herpes or varicella virus infection. In CMV retinitis, if ganciclovir cannot be tolerated: If no response is seen the dose should be increased to the CMV dose given above. One litre of sodium chloride 0.
This is not necessary after the patient has been reduced to maintenance doses. Foscarnet is extremely nephrotoxic, regular monitoring of renal function should occur during treatment twice a week and maintenance once every two weeksand the dose adjusted appropriately.
There is a high incidence of hypocalcaemia, hypokalaemia, hypophosphataemia and hypomagnesaemia: Foscarnet concentrates fowcarnet the urine and can cause genital ulceration especially in men with foreskins. At the start of therapy all patients should be told to wash the genital area with soap and water after they have urinated.
Skeletal abnormalities have been seen in animal studies. However, the data was insufficient to define the potential teratogenicity of foscarnet in humans at the dosages used. Therefore, foscarnet should only be used in pregnancy if the potential benefits outweigh the risks to the foetus.
Nephrotoxicity, hypomagnesaemia, hypocalcaemia, hypokalaemia, hypophosphataemia, hypercalcaemia accompanied by perioral tingling, numbness in the extremities, paraesthesiahyperphosphataemia, headache, nausea, vomiting, rash, convulsions though to be associated infotmation hypocalcaemiagenital ulceration, and anaemia. Concurrent administration of other nephrotoxic drugs during treatment with foscarnet i. During the maintenance phase, if there are no alternative therapies, they should be used with extreme caution.
Foscarnet Injection: MedlinePlus Drug Information
Overdose has been reported in 33 patients, the highest dose being about 10 times the prescribed dose. Twenty-eight of the patients experienced adverse events and five patients suffered no ill effects in connection with foscarnet overdosing. The pattern of adverse events reported in connection with overdose was in correspondence with the symptoms previously observed during foscarnet therapy.
Clinical information Uses Treatment of cytomegalovirus end organ disease and maintenance of CMV retinitis. Treatment of resistant herpes or varicella virus infection Dosage and administration Treatment of cytomegalovirus end organ disease and maintenance prescribimg CMV retinitis. Use in pregnancy Skeletal abnormalities have been seen in animal studies. Adverse effects Nephrotoxicity, hypomagnesaemia, hypocalcaemia, hypokalaemia, hypophosphataemia, hypercalcaemia accompanied by perioral tingling, numbness in the extremities, paraesthesiahyperphosphataemia, headache, nausea, vomiting, rash, convulsions though to be associated with hypocalcaemiagenital ulceration, and anaemia.
Drug interactions Concurrent administration of other nephrotoxic drugs pprescribing treatment with foscarnet i.
Foscarnet – DrugBank
Overdosage Overdose has focarnet reported in 33 patients, the highest dose being about 10 times the prescribed dose. Haemodialysis increases foscarnet elimination and may be of value in severe overdose. Site of disease – Potential opportunistic of disease. Pneumonia due to Pneumocystis carinii PCP. Mycobacterium avium complex MAC.
Mucocutaneous and cutaneous eruptions. Oral and oesophageal candidiasis.